Aptevo reports 93% clinical benefit rate with mipletamig triplet
Aptevo Therapeutics said mipletamig triplet produced a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML, with remission results described as nearly doubling published ven/aza outcomes.
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment successSEATTLE, WA / / September 3, 2026 / Aptevo Therapeutics Inc.
NASDAQ:APVO, a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeut…